Eli Lilly (NEO:LLY)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Eli Lilly Charts. Click Here for more Eli Lilly Charts.](/p.php?pid=staticchart&s=NEO%5ELLY&p=8&t=15)
Cymbalta(R) Helped Patients with Depression Feel Better Fast,
According to Pooled Data from Two 9-week Trials
NEW YORK, May 5 /PRNewswire-FirstCall/ -- Patients treated with 60 mg per day
of the investigational antidepressant Cymbalta(R) (duloxetine hydrochloride),
experienced significant improvements in both mood and painful physical symptoms
after one week, according to pooled data from two 9-week studies presented at
the American Psychiatric Association meeting.
The data show that response to Cymbalta was fastest for the core emotional and
painful physical symptoms of depression. After the first week of treatment,
significant improvements were observed in depressed mood, feelings of guilt,
suicidal ideation, work and activities, anxiety, back pain and shoulder pain.
"Patients are more likely to stay on a medication if they feel symptom relief
early on in the course of treatment," said Robert Hirschfeld, M.D., Titus
Harris Chair and Professor and Chair of Psychiatry and Behavioral Sciences at
the University of Texas Medical Branch in Galveston. "These data demonstrate
that in these patients duloxetine was effective at providing improvements in
several symptoms of depression as early as one week."
Complete elimination of symptoms, or remission, is the primary goal of
depression treatment. Treating the full spectrum of emotional and physical
symptoms to remission puts patients at a decreased risk of relapse.(1, 2) Among
the 19 million Americans with depression annually, an estimated 50 percent will
suffer a relapse within two years.(3)
Cymbalta, is a potent serotonin and norepinephrine reuptake inhibitor. It is
being reviewed by the U.S. Food and Drug Administration as a potential
treatment for Major Depressive Disorder.
Additional Study Highlights
* At week one, patients treated with Cymbalta experienced greater improvement
in core emotional (depressed mood, guilt, suicidal ideation, work/activities,
psychic anxiety) and physical symptoms (back and shoulder pain) of depression
compared with patients treated with sugar pills.
* In patients treated with Cymbalta, greater improvements in sleep, genital
and non-painful somatic symptoms were achieved between five and nine weeks.
* At weeks one and two, patients treated with sugar pills experienced greater
improvement in somatic gastrointestinal (GI) symptoms and weight loss than
patients taking Cymbalta; by week nine, however, Cymbalta-treated patients
experienced significant improvements in somatic GI symptoms in comparison with
patients taking sugar pills.
Methods
Data were pooled from two identical, randomized, double-blind, parallel- group,
placebo-controlled studies. Participants were males and females, 18 years of
age and older, who met DSM-IV criteria for major depressive disorder, had
Hamilton Depression Rating Scale (HAMD17) scores of >/= 15 and Clinical Global
Impression-Severity (CGI-S) scores of >/= 4 at baseline. Patients were not
pre-screened for pain.
Patients were randomized to receive 60 mg once daily of Cymbalta (n=244) or
placebo (n=251) for up to 9 weeks. Mean changes in individual HAMD17 items and
a visual analog scale (VAS) for pain (overall, shoulder and back) were
analyzed.
About Cymbalta
In placebo-controlled clinical trials for Major Depressive Disorder, the most
commonly observed adverse events (>/= 5 percent and at least twice placebo) for
Cymbalta vs. placebo (n = 1,139 vs. 777) were: nausea (20 percent vs. 7
percent), dry mouth (15 percent vs. 6 percent), constipation (11 percent vs. 4
percent), decreased appetite (8 percent vs. 2 percent), fatigue (8 percent vs.
4 percent), sleepiness (7 percent vs. 3 percent), and increased sweating (6
percent vs. 2 percent). The overall discontinuation rate due to adverse events
for Cymbalta vs. placebo was 10 percent vs. 4 percent. Nausea was the only
common adverse event reported as a reason for discontinuation and considered to
be drug related (1.4 percent vs. 0.1 percent).
The US Food and Drug Administration issued an approvable letter for Cymbalta
(duloxetine for depression) in September 2003. Duloxetine hydrochloride also
is being studied by Lilly for the treatment of stress urinary incontinence and
diabetic neuropathic pain. All three conditions are believed to be mediated by
serotonin and norepinephrine.
About Lilly
Lilly, a leading innovation-driven corporation, is developing a growing
portfolio of first-in-class and best-in-class pharmaceutical products by
applying the latest research from its own worldwide laboratories and from
collaborations with eminent scientific organizations. Headquartered in
Indianapolis, Ind., Lilly provides answers -- through medicines and information
-- for some of the world's most urgent medical needs. Additional information
about Lilly is available at http://www.lilly.com/ .
This press release contains forward-looking statements about the potential of
an investigational compound, duloxetine, for the treatment of depression and
reflects Lilly's current beliefs. However, as with any pharmaceutical product
under development, there are substantial risks and uncertainties in the process
of development and regulatory review. There is no guarantee that the product
will receive regulatory approvals, or that the regulatory approval will be for
the indications(s) anticipated by the company. There is also no guarantee that
the product will prove to be commercially successful. For further discussion
of these and other risks and uncertainties, see Lilly's filing with the United
States Securities and Exchange Commission. Lilly undertakes no update to
forward-looking statements.
1. Nierenberg, A. Long-Term Management of Chronic Depression. J Clin Psychiatry
2001; 62 (Suppl 6): 17-20
2. Delgado, P. Approaches to the Enhancement of Patient Adherence to
Antidepressant Medication Treatment. J Clin Psychiatry 2000; 61 (Suppl 6): 6-9
3. Hirschfeld RMA, Keller MB, Panico S, et. al. The National Depressive and
Manic Depressive Association Consensus Statement on the Undertreatment of
Depression. JAMA, 1997; 277; 333-340
(Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO )
http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO
DATASOURCE: Eli Lilly and Company
CONTACT: David Shaffer (US), +1-317-651-3710, cell: +1-317-997-0632, or
Jennifer Yoder (OUS), +1-317-433-3445, cell: +1-317-652-0912, both of Eli
Lilly and Company